Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/13/2026

1. CRWV
2. SMCI
3. GAMI
4. LITE
5. SPY
6. ONON
7. CAVA
8. CSCO
9. NTHI
10. ETOR

Go back to Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
(NASDAQ: FULC) Delayed: 3.72 --0 (-0%)
Previous Close $3.72    52 Week High $ 
Open $3.72    52 Week Low $ 
Day High $3.72    P/E N/A 
Day Low $3.72    EPS $ 
Volume 143       

SANOFI (NASDAQ: SNY) Delayed: 43.71 --0 (-0%)
Previous Close $43.71    52 Week High $44.76 
Open $43.71    52 Week Low $36.81 
Day High $43.71    P/E N/A 
Day Low $43.71    EPS $0.00 
Volume 14,354